Shots:
- Ionis & Roche have reported interim P-III (IMAgINATION) trial results assessing sefaxersen (QM, SC) in 459 adults with IgAN for 105wks., after which eligible pts may switch to open-label treatment
- IMAgINATION met its 1EP, showing improvements in proteinuria reduction at 37wks., as measured by 24hr. UPCR; data to be presented in future & shared with global health authorities
- Trial will continue to assess sefaxersen, a highly specific liver-directed ASO designed to inhibit factor B production, as a blinded study to evaluate the change in kidney function over 2yrs., as measured by eGFR at Wk. 105
Ref: Businesswire | Image: Ionis & Roche | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
